Viscosupplementation Market is projected to grow to US$ 12.94 Billion By 2032, exhibiting a CAGR of 10.6% from 2024 to 2032 | PMR

The global viscosupplementation Market is expected to reach USD 12.94 billion in 2032, growing at a 10.6% CAGR from 2024-2032. It was valued at USD 5.27 billion in 2023. The market is encountering substantial growth and is anticipated to carry on with augmenting in the coming years.

In the course of viscosupplementation treatment for arthritis, the healthcare donor injects hyaluronic acid into the joints. The dense fluid may decrease pain and swelling in the arthritic joint. The bones that frame the joints normally possess a cap of cartilage on their ends.

This cartilage assists in ascertaining that the bones move seamlessly against each other. The cartilage has a fluid covering that comprises hyaluronic acid. This operates like a lubricant and shock absorber in the joints.

𝐅𝐢𝐥𝐥 𝐮𝐩 𝐚 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐞𝐦𝐚𝐢𝐥 𝐭𝐨 𝐠𝐞𝐭 𝐚 𝐟𝐫𝐞𝐞 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐬𝐮𝐦𝐦𝐚𝐫𝐲 𝐫𝐢𝐠𝐡𝐭 𝐧𝐨𝐰 @ https://www.polarismarketresearch.com/industry-analysis/viscosupplement-market/request-for-sample

Competitive Landscape

Medical technology progressions, hastened trial acceptance, contemporary commodity instigations, mergers & acquisitions, partnerships, and other creations have been cultivated by prominent firms. Some of the major players in the market include:

Market Highlights
• The viscosupplementation market demand is on the rise for nonsurgical solutions for osteoarthritis, lifestyle-connected situations, and progressions in the advancement of therapies utilizing hyaluronic acid.
• Additionally, the viscosupplementation market size is expanding as worldwide compensated topography is expected to become more approved, sanctioning the accessibility of osteoarthritis cures.
• Asia Pacific dominated the market in 2023
• Europe is anticipated to grow swiftly in the course of the forecast period.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.polarismarketresearch.com/buy/5/2

Polaris Market Research has segmented the Viscosupplementation market report based on product, end-use, and region:
Viscosupplementation, Product Outlook (Revenue - USD Billion, 2019 - 2032)
 Three Injection
 Five Injection
 Single Injection
Viscosupplementation, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)
 Orthopedic Clinics/ASCs
 Hospitals
Viscosupplementation, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
 North America
o U.S.
o Canada
 Europe
o Germany
o UK
o France
o Italy
o Spain
o Russia
o Netherlands
 Asia Pacific
o China
o India
o Japan
o South Korea
o Indonesia
o Malaysia
 Latin America
o Argentina
o Brazil
o Mexico
 Middle East & Africa
o UAE
o Saudi Arabia
o Israel
o South Africa
𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐭𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.polarismarketresearch.com/press-releases/viscosupplementation-market

Viscosupplementation Market Report Highlights
• In 2022, the Three Injection segment dominated the market in terms of revenue. The three-injection procedure stands out as the preferred method for treating osteoarthritis, chosen by medical practitioners for its effectiveness.

This approach is commonly favored to reduce the necessity for total knee replacement surgery in cases of osteoarthritis, influencing the market share. The availability of various three-injection segments further contributes to this trend. Additionally, the approval of numerous clinical trials showcasing positive results for three-injection procedures in osteoarthritis treatment adds to the segment's significance.

• During the forecast period, the highest market share was attributed to the Orthopedic Clinics/ASCs segment. This dominance is driven by the rising demand for outpatient surgeries, with orthopedic clinics focusing on comprehensive musculoskeletal care encompassing both surgical and nonsurgical interventions for the spine, joints, ligaments, bones, muscles, and nerves. The notable increase in the prevalence of osteoarthritis among the elderly population is a key factor expected to contribute significantly to the growth of this segment.

• In 2022, Asia Pacific emerged as the dominant market, with its growth being prominently driven by the presence of a susceptible geriatric population prone to osteoarthritis. Furthermore, the market expansion is bolstered by various initiatives focused on strengthening the overall market landscape in the region.

• The global key market players include Anika Therapeutics, Inc., DePuy Synthes, F.Hoffmann-La Roche Ltd., Ferring Pharmaceuticals B.V., Fidia Farmaceutici S.p.A, LG Life Sciences Ltd., Lifecore Biomedical, Sanofi, Seikagaku Corp., Smith & Nephew PLC, Zimmer Biomet.

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 (𝐀𝐈) 𝐢𝐧 𝐌𝐞𝐧𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.openpr.com/news/3416040/artificial-intelligence-ai-in-mental-health-market

𝐍𝐞𝐨𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.openpr.com/news/3416048/neobanking-market-share-to-reach-usd-4784-54-billion-globally

𝐒𝐨𝐮𝐫𝐝𝐨𝐮𝐠𝐡 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.openpr.com/news/3416085/sourdough-market-rising-trends-growth-projections-and-key

𝐒𝐩𝐢𝐜𝐞𝐬 𝐚𝐧𝐝 𝐒𝐞𝐚𝐬𝐨𝐧𝐢𝐧𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.openpr.com/news/3416095/spices-and-seasoning-market-research-report-2024-2032

𝐒𝐮𝐩𝐞𝐫𝐟𝐨𝐨𝐝𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.openpr.com/news/3416101/superfoods-market-business-revenue-industry-dynamics

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐈𝐧𝐟𝐨:

Polaris Market Research
30 Wall Street, 8th Floor,
New York City, NY 10005,
United States
Phone:+1-929 297-9727
Email: sales@polarismarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defence, among different ventures present globally.

This release was published on openPR.